leadf
logo-loader
viewOutlook Therapeutics
(
NASDAQ:OTLK
)

Outlook Therapeutics' wet AMD therapy study results validates expectations, looks forward to Phase 3

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CEO Lawrence Kenyon tells Proactive the clinical-stage biopharmaceutical company says its ONS-5010 therapy to treat wet AMD revealed positive proof-of-concept results.

Kenyon says investors should understand that this small, 60-patient clinical study was not expected to achieve statistical significance, however, its pivotal NORSE 2 pivotal trial will reveal these results.

Quick facts: Outlook Therapeutics

Follow
NASDAQ:OTLK

Price: 2.3 USD

Market Cap: $403.28 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ixico seeing success with a number of contracts awarded covering multiple...

Ixico plc Chief Commercial Officer Lammert Albers joined Steve Darling from Proactive to share news the Clinical Research Organization has awarded the company, on behalf of their biopharmaceutical sponsor,  a 6-figure deal to conduct a Phase II Alzheimer’s disease clinical trial.  Albers...

4 hours, 10 minutes ago

2 min read